Edatrexate studies in non-small cell lung cancer

Richard J. Gralla

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Edatrexate (10-ethyl-10-deaza-aminopterin, or 10-EDAM) is a water-soluble antifolate which is under study in a variety of malignancies. Edatrexate demonstrated greater antitumor activity than methotrexate in several solid tumor models and xenografts, which may be due to a more extensive formation of polyglutaminates within tumor cells by edatrexate metabolites. Phase I studies have recommended a dose of 80 mg/m2 i.v. weekly for tumor specific trials. When used with leucovorin, edatrexate doses more that 10 times as high have been found to be well-tolerated. Dose-limiting toxicity is mucositis, with leukopenia and thrombocytopenia being less prominent. In three Phase II trials without leucovorin in non-small cell lung cancer, edatrexate has shown an overall objective major response rate of 17% in 66 previously untreated patients (95% C.I.: 9-28%), making it one of the more active single agents in this malignancy. With its relatively low degree of myelosuppression, edatrexate has been an attractive agent for use in combination. To date, trials combining this drug with mitomycin plus vinblastine, cisplatin plus cyclophosphamide, paclitaxel, and carboplatin have been initiated. The encouraging response rates and low degree of toxicity make this agent interesting for further investigation in non-small cell lung cancer.

Original languageEnglish (US)
JournalLung Cancer
Volume12
Issue numberSUPPL. 1
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Leucovorin
Neoplasms
Folic Acid Antagonists
Mucositis
Vinblastine
edatrexate
Carboplatin
Leukopenia
Mitomycin
Paclitaxel
Heterografts
Methotrexate
Thrombocytopenia
Cyclophosphamide
Cisplatin
Water
Pharmaceutical Preparations

Keywords

  • Antifolate
  • Chemotherapy
  • Combination chemotherapy
  • Edatrexate
  • Non-small cell lung cancer
  • Phase I trial
  • Phase II trial

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Edatrexate studies in non-small cell lung cancer. / Gralla, Richard J.

In: Lung Cancer, Vol. 12, No. SUPPL. 1, 1995.

Research output: Contribution to journalArticle

Gralla, Richard J. / Edatrexate studies in non-small cell lung cancer. In: Lung Cancer. 1995 ; Vol. 12, No. SUPPL. 1.
@article{d9079a59ec9c48cab09f8bd333a56c27,
title = "Edatrexate studies in non-small cell lung cancer",
abstract = "Edatrexate (10-ethyl-10-deaza-aminopterin, or 10-EDAM) is a water-soluble antifolate which is under study in a variety of malignancies. Edatrexate demonstrated greater antitumor activity than methotrexate in several solid tumor models and xenografts, which may be due to a more extensive formation of polyglutaminates within tumor cells by edatrexate metabolites. Phase I studies have recommended a dose of 80 mg/m2 i.v. weekly for tumor specific trials. When used with leucovorin, edatrexate doses more that 10 times as high have been found to be well-tolerated. Dose-limiting toxicity is mucositis, with leukopenia and thrombocytopenia being less prominent. In three Phase II trials without leucovorin in non-small cell lung cancer, edatrexate has shown an overall objective major response rate of 17{\%} in 66 previously untreated patients (95{\%} C.I.: 9-28{\%}), making it one of the more active single agents in this malignancy. With its relatively low degree of myelosuppression, edatrexate has been an attractive agent for use in combination. To date, trials combining this drug with mitomycin plus vinblastine, cisplatin plus cyclophosphamide, paclitaxel, and carboplatin have been initiated. The encouraging response rates and low degree of toxicity make this agent interesting for further investigation in non-small cell lung cancer.",
keywords = "Antifolate, Chemotherapy, Combination chemotherapy, Edatrexate, Non-small cell lung cancer, Phase I trial, Phase II trial",
author = "Gralla, {Richard J.}",
year = "1995",
doi = "10.1016/0169-5002(95)00435-4",
language = "English (US)",
volume = "12",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Edatrexate studies in non-small cell lung cancer

AU - Gralla, Richard J.

PY - 1995

Y1 - 1995

N2 - Edatrexate (10-ethyl-10-deaza-aminopterin, or 10-EDAM) is a water-soluble antifolate which is under study in a variety of malignancies. Edatrexate demonstrated greater antitumor activity than methotrexate in several solid tumor models and xenografts, which may be due to a more extensive formation of polyglutaminates within tumor cells by edatrexate metabolites. Phase I studies have recommended a dose of 80 mg/m2 i.v. weekly for tumor specific trials. When used with leucovorin, edatrexate doses more that 10 times as high have been found to be well-tolerated. Dose-limiting toxicity is mucositis, with leukopenia and thrombocytopenia being less prominent. In three Phase II trials without leucovorin in non-small cell lung cancer, edatrexate has shown an overall objective major response rate of 17% in 66 previously untreated patients (95% C.I.: 9-28%), making it one of the more active single agents in this malignancy. With its relatively low degree of myelosuppression, edatrexate has been an attractive agent for use in combination. To date, trials combining this drug with mitomycin plus vinblastine, cisplatin plus cyclophosphamide, paclitaxel, and carboplatin have been initiated. The encouraging response rates and low degree of toxicity make this agent interesting for further investigation in non-small cell lung cancer.

AB - Edatrexate (10-ethyl-10-deaza-aminopterin, or 10-EDAM) is a water-soluble antifolate which is under study in a variety of malignancies. Edatrexate demonstrated greater antitumor activity than methotrexate in several solid tumor models and xenografts, which may be due to a more extensive formation of polyglutaminates within tumor cells by edatrexate metabolites. Phase I studies have recommended a dose of 80 mg/m2 i.v. weekly for tumor specific trials. When used with leucovorin, edatrexate doses more that 10 times as high have been found to be well-tolerated. Dose-limiting toxicity is mucositis, with leukopenia and thrombocytopenia being less prominent. In three Phase II trials without leucovorin in non-small cell lung cancer, edatrexate has shown an overall objective major response rate of 17% in 66 previously untreated patients (95% C.I.: 9-28%), making it one of the more active single agents in this malignancy. With its relatively low degree of myelosuppression, edatrexate has been an attractive agent for use in combination. To date, trials combining this drug with mitomycin plus vinblastine, cisplatin plus cyclophosphamide, paclitaxel, and carboplatin have been initiated. The encouraging response rates and low degree of toxicity make this agent interesting for further investigation in non-small cell lung cancer.

KW - Antifolate

KW - Chemotherapy

KW - Combination chemotherapy

KW - Edatrexate

KW - Non-small cell lung cancer

KW - Phase I trial

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0029001361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029001361&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(95)00435-4

DO - 10.1016/0169-5002(95)00435-4

M3 - Article

C2 - 7551928

AN - SCOPUS:0029001361

VL - 12

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 1

ER -